The goal of this prospective, multi-center, randomized double-arm clinical trial is to demonstrate a benefit in term of local control of a shorter spread of hypofractionated stereotactic radiotherapy at D1-2-3 vs D1-3-5, in the treatment of "radioresistant" Brain Metastases (BM). This trial aims to recruit patients with 1 to 5 unoperated BM originating from radioresistant primary sites. Patients will be randomly assigned to either the D1-3-5 radiotherapy arm or the D1-2-3 radiotherapy arm. Stereotactic brain irradiation will be administered at a dose of 33 Gy delivered in 3 fractions.
Age > 18 years
Patients with one or more unoperated brain metastases (1-5) originating from radioresistant primary locations, including melanoma, kidney, digestive, sarcoma, and prostate *
Karnofsky Performance Status (KPS) greater than 50% (Annex 3).
Absence of major psychiatric conditions in the medical history that may interfere with follow-up, based on the investigator's judgement.
Pregnant or breastfeeding women
An unoperated brain metastasis whose maximum diameter is > 3.5 cm
Patients deprived of liberty or under guardianship (including curatorship).
Patients with a history of cerebral radiotherapy.